FDA deal with data provider on opioid misuse faces pushback; another major pharma company leaves BIO

Taking stock of the drug industry, from the lab to the medicine chest

January 4, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

ERIC BARADAT/AFP via Getty Images STAT+ | FDA is blasted by advocates for pursuing a deal with data provider that has ties to opioid makers Advocates maintain there are more independent sources of data that could help the FDA monitor the misuse of prescription opioids. By Ed Silverman STAT+ | Another major pharma company departs BIO UCB left the biotech industry group BIO at the end of 2023, the second major member company to exit after Pfizer pulled out. By Rachel Cohrs STAT+ | Feng Zhang's year-old CRISPR delivery startup Aera lays off quarter of staff The layoffs come amid a biotech market downturn. Aera is one of several startups trying to solve a key bottleneck in genetic medicine. By Jason Mast Alex Hogan/STAT STAT+ | Burning questions for the 2024 JPM Healthcare Conference The J.P. Morgan conference, which begins Monday in San Francisco, will be a barometer of whether newfound optimism in biotech will persist in 2024. By Damian Garde and Adam Feuerstein and Allison DeAngelis and Matthew Herper and Mohana Ravindranath STAT+ | An injectable gel enters the male birth control fray with early positive clinical data An injectable, reversible hydrogel made by Contraline could fill the male birth control void between condoms and vasectomies. By Lizzy Lawrence STAT+ | Allogene to pursue new strategy for development of off-the-shelf cell therapy in blood cancer Company is ending late-stage lymphoma trials and will test therapy on earlier cancers, a concession to competition from personalized CAR-T. By Adam Feuerstein LISELOTTE SABROE/Scanpix/AFP via Getty Images STAT+ | Novo Nordisk enlists two Flagship biotechs to develop obesity, MASH drugs The deals, which are valued at as much as $1.06 billion, are focused on developing treatments for obesity and MASH. By Allison DeAngelis STAT+ | Feng Zhang, Grail founder join forces on new gene editing startup, Moonwalk The company, Moonwalk, has raised $57 million to develop a defanged form of gene editing that doesn't cut the DNA strand. By Allison DeAngelis

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser